Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

Core Insights - Protagonist Therapeutics, a clinical-stage biotech company, reported significant insider selling by director William D. Waddill, who sold 20,000 shares for approximately $1.7 million, despite the company's strong stock performance [1][2]. Company Overview - Protagonist Therapeutics focuses on peptide therapeutics to address unmet medical needs in hematology and immunology, particularly for patients with rare blood disorders and inflammatory diseases [5]. - As of February 14, 2026, the company's stock price was $81.49, with a market capitalization of $5.09 billion, revenue of $209.22 million, and net income of $45.91 million [4]. Transaction Details - The sale of 20,000 shares is five times larger than Waddill's recent median sell transaction of 4,000 shares, indicating a significant move [7]. - The transaction occurred when the stock was priced at $83.68, reflecting a 123.8% increase over the previous twelve months [7][8]. Market Context - Protagonist highlighted its projected growth at the J.P. Morgan Healthcare Conference, with two key pharmaceutical products in advanced clinical development, supported by major firms like Johnson & Johnson [8]. - Despite the insider selling, Wall Street analysts predominantly rate Protagonist's stock as a "strong buy," with a high price-to-earnings ratio of 113.15, suggesting strong growth expectations [6].